The goals of this Program are to delineate in vivo functions of the human RecQ helicase proteins, and to understand how loss of RecQ helicase function leads to genetic instability, an elevated risk of cancer and selective sensitivity to cancer chemotherapeutic agents. Our long term goal is to use new information on the human RecQ proteins to modify or limit disease risk or progression, and to devise novel, targeted anticancer therapies. In order to achieve these goals, we have developed an integrated research Program of 4 Projects and 2 Cores focused on three Experimental Aims. Our revised Aims are:
Aim 1 : to determine molecular and mechanistic aspects of RecQ helicase function in human cells;
Aim 2 : to determine how loss of RecQ helicase function promotes genetic instability, limits cell proliferation and leads to heightened sensitivity to cancer chemotherapeutic agents including topoisomerase I inhibitors and DNA cross linking drugs;
and Aim 3 : to determine how RecQ helicases can be further developed as biomarkers and targets to modify cancer risk and to improve the response or devise new approaches to chemotherapy of human colorectal and breast carcinomas. This revised Renewal incorporates a newly developed and substantially expanded research emphasis on human tumors, patient cohorts and genetically defined populations. The Program as a whole reflects a growing recognition of the role for RecQ helicases in human biology and disease, most notably in cancer biology and the response to cancer chemotherapy. Thus the proposed research will have substantial basic science, clinical and translational potential. We plan to fully develop these opportunities in the proposed research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Program Officer
Okano, Paul
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Schools of Medicine
United States
Zip Code
Shiovitz, Stacey; Bertagnolli, Monica M; Renfro, Lindsay A et al. (2014) CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 147:637-45
Shen, Jiang-Cheng; Fox, Edward J; Ahn, Eun Hyun et al. (2014) A rapid assay for measuring nucleotide excision repair by oligonucleotide retrieval. Sci Rep 4:4894
Yu, M; Trobridge, P; Wang, Y et al. (2014) Inactivation of TGF-* signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene 33:1538-47
Luo, Yanxin; Wong, Chao-Jen; Kaz, Andrew M et al. (2014) Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology 147:418-29.e8
Kamath-Loeb, Ashwini S; Balakrishna, Sharath; Whittington, Dale et al. (2014) Sphingosine, a modulator of human translesion DNA polymerase activity. J Biol Chem 289:21663-72
Lauper, Julia M; Monnat Jr, Raymond J (2014) Diabetes mellitus and cancer in Werner syndrome. Acta Diabetol 51:159-61
Pavelitz, Thomas; Renfro, Lindsay; Foster, Nathan R et al. (2014) MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. PLoS One 9:e108483
Kiianitsa, Kostantin; Maizels, Nancy (2014) Ultrasensitive isolation, identification and quantification of DNA-protein adducts by ELISA-based RADAR assay. Nucleic Acids Res 42:e108
Gray, Lucas T; Vallur, Aarthy C; Eddy, Johanna et al. (2014) G quadruplexes are genomewide targets of transcriptional helicases XPB and XPD. Nat Chem Biol 10:313-8
Grady, William M; Pritchard, Colin C (2014) Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 42:124-39

Showing the most recent 10 out of 84 publications